Abstracts tagged "Biomarkers"

Abstract Number: 1693 • ACR Convergence 2023
Blood Immunophenotyping Distinguishes Three Subgroups of Lupus Nephritis Patients with Distinct Kidney Infiltrates and Interferon Signatures
Alice Horisberger¹, Alec Griffith¹, Arnon Arazi², Joshua Keegan¹, Kaitlyn Howard¹, Takanori Sasaki¹, Tusharkanti Ghosh³, Andrea Fava⁴, Jun Inamo⁵, John Pulford¹, Ekaterina Murzin¹, Brandon Hancock¹, Katie Preisinger⁶, Maria Gutierrez-Arcelus⁷, Thomas Eisenhaure⁸, Joel Guthridge⁹, Paul Hoover¹⁰, Maria Dall'Era¹¹, David Wofsy¹¹, Diane L. Kamen¹², Kenneth Kalunian¹³, Richard Furie¹⁴, H Michael Belmont¹⁵, Peter Izmirly⁶, Robert Clancy¹⁶, David Hildeman¹⁷, steve Woodle¹⁷, William Apruzzese¹⁸, Maureen McMahon¹⁹, Jennifer Grossman²⁰, Jennifer Barnas²¹, Fernanda Payan-Schober²², Mariko Ishimori²³, Accelerating Medicines Partnership Program RA SLE Network²³, Matthias Kretzler²⁴, Celine Berthier²⁴, Jeff Hodgin²⁴, Dawit Demeke²⁴, Chaim Putterman²⁵, Nir Hacohen⁸, Michael Brenner¹, Jennifer Anolik²¹, Anne Davidson²⁶, Judith James⁹, Soumya Raychaudhuri¹⁰, Michelle Petri²⁷, Jill Buyon¹⁶, Betty Diamond²⁶, The Accelerating Medicines Partnership In RA/SLE²⁸, Fan Zhang²⁹, James Lederer¹ and Deepak Rao¹⁰, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Broad Institute of MIT and Harvard, Melrose, MA, ³School of Public Health, University of Colorado, Anschutz Medical Campus, Aurora, CO, ⁴Johns Hopkins University, Baltimore, MD, ⁵University of Colorado School of Medicine, Aurora, CO, ⁶New York University School of Medicine, New York, NY, ⁷Boston Children's Hospital, Boston, MA, ⁸Broad Institute of MIT and Harvard, Cambridge, MA, ⁹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁰Brigham and Women's Hospital, Boston, MA, ¹¹University of California San Francisco, San Francisco, CA, ¹²Medical University of South Carolina, Charleston, SC, ¹³University of California San Diego, La Jolla, CA, ¹⁴Northwell Health, Manhasset, NY, ¹⁵NYU School of Medicine, New York, NY, ¹⁶NYU Grossman School of Medicine, New York, NY, ¹⁷University of Cincinnati College of Medicine, Cincinnati, OH, ¹⁸Accelerating Medicines Partnership® Program: Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) Network, Boston, MA, ¹⁹UCLA David Geffen School of Medicine, Los Angeles, CA, ²⁰University of California Los Angeles, Los Angeles, CA, ²¹University of Rochester Medical Center, Rochester, NY, ²²Texas Tech University Health Sciences Center, El Paso, TX, ²³Cedars-Sinai Medical Center, Los Angeles, CA, ²⁴University of Michigan, Ann Arbor, MI, ²⁵Albert Einstein College of Medicine, Bronx, NY, ²⁶Feinstein Institutes for Medical Research, Manhasset, NY, ²⁷Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ²⁸multisites, multisites, ²⁹University of Colorado, Aurora, CO
Background/Purpose: Patients with lupus nephritis (LN) have variable responses to standard-of-care therapy, and a third of patients with class III, IV, or V show a…
Abstract Number: 1795 • ACR Convergence 2023
Multi-Omics Analyses Identify Metabolic Pathways That Differentiate Psoriatic Arthritis from Psoriasis
Chiara Pastrello¹, Darshini Ganatra², Max Kotlyar¹, Nikita Looby², Quan Li³, Lihi Eder⁴, Dafna Gladman⁵, Proton Rahman³, Igor Jurisica⁶ and Vinod Chandran⁷, ¹Osteoarthritis Research Program, Division of Orthopaedic Surgery, Schroeder Arthritis Institute and Data Science Discovery Centre for Chronic diseases, Krembil Research Institute, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³Craig Dobbin Research Institute, Memorial University, St. John's, NL, Canada, ⁴Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute and Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, ⁷Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a form of inflammatory arthritis that occurs in patients with cutaneous psoriasis. Due to the lack of clinically useful diagnostic…
Abstract Number: 2297 • ACR Convergence 2023
Interferon-α as a Biomarker to Predict Flares in Lupus Nephritis
Laura Patricia Whittall Garcia¹, Dafna Gladman², Murray Urowitz³, Zahi Touma⁴ and Joan Wither¹, ¹University Health Network, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Type I Interferons (IFN-I) play a role in SLE and Lupus Nephritis (LN) pathogenesis. We have recently shown that IFN-I gene expression predicts the…
Abstract Number: 2368 • ACR Convergence 2023
Is Skin Disease a Local Manifestation of Systemic Tissue Turnover? Serological Collagen Biomarkers Provide Important Information on Skin Diseases Arising from Mutations in Collagen Genes
Signe Holm Nielsen¹, Matej Anđelić², Dovile Sinkeviciute¹, Anne-Christine Bay-Jensen¹ and Morten Karsdal¹, ¹Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, Copenhagen, Denmark
Background/Purpose: Collagens are the main constituents of the skin. Genetic mutations in type VI, VII, and XVII collagen cause skin diseases, such as atopic dermatitis,…
Abstract Number: 2584 • ACR Convergence 2023
Gut Microbiome and Intestinal Inflammation in Preclinical Stages of Rheumatoid Arthritis
Benoît Thomas P. GILBERT¹, Raul Yhossef TITO TADEO², Céline LAMACCHIA¹, Olivia STUDER¹, Delphine COURVOISIER¹, Jeroen RAES³ and Axel Finckh⁴, ¹Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ²Center for Microbiology, VIB, Leuven. Laboratory of Molecular Bacteriology, Department of Microbiology and Immunology, Rega Institute, Katholieke Universiteit Leuven, Leuven, Belgium, ³Center for Microbiology, VIB, Leuven. Laboratory of Molecular Bacteriology, Department of Microbiology and Immunology, Rega Institute, Katholieke Universiteit Leuven., Leuven, Belgium, ⁴HUG, Geneva, Switzerland
Background/Purpose: We attempted to replicate and expand previous findings of an increased abundance of Prevotellaceae in early untreated Rheumatoid Arthritis (RA) or its preclinical stages,…
Abstract Number: 0101 • ACR Convergence 2023
Non-Criteria Antiphospholipid Antibodies and Calprotectin as Potential Biomarkers in Pediatric Antiphospholipid Syndrome
Elizabeth Sloan¹, Katarina Kmetova², NaveenKumar K. Somanathapura², Lyndsay Kluge², Emily Chong², Claire Hoy², Srilakshmi Yalavarthi², Jacqueline Madison², Cyrus Sarosh², Lynnette Walters³, Jeanine Baisch⁴, Jessica Turnier², Virginia Pascual⁴, Tracey Wright¹, Jason Knight², Ayesha Zia¹ and Yu Zuo², ¹UT Southwestern, Dallas, TX, ²University of Michigan, Ann Arbor, MI, ³Scottish Rite Hospital for Children, Dallas, TX, ⁴Weill Cornell Medicine, New York, NY
Background/Purpose: While classification criteria for pediatric APS are not yet available, recent research suggests pediatric APS patients are unique, and many present with extra-criteria manifestations…
Abstract Number: 0544 • ACR Convergence 2023
Autoantibodies to dsDNA and Associated Proteins: Association with Proteinuria and Lupus Nephritis
Ranjan Gupta¹, Amita Aggarwal², Avinash Jain³, Liza Rajasekhar⁴, Chengappa Kavadichanda⁵, Vineeta Shobha⁶, Ashish J Mathew⁷, Parasar Ghosh⁸, Bidyut Das⁹ and Manish Rathi¹⁰, ¹All India Institute of Medical Sciences, New Delhi, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ³SMS Medical College, Lucknow, India, ⁴Nizam's Institute of Medical Sciences, Madhapur, India, ⁵Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ⁶St. John's National Academy of Health Science, Bangalore, India, ⁷Christian Medical College, Vellore, India, ⁸Govt of West Bengal, Kolkata, India, ⁹SCB medical college, Cuttack, India, ¹⁰Postgraduate Institute of Medical education and Research, Chandigarh, India
Background/Purpose: Anti-dsDNA antibodies (ADA) are traditionally measured by ELISA and are associated with Lupus nephritis (LN). Testing by immunoline assay (IL) provides additional information on…
Abstract Number: 0627 • ACR Convergence 2023
Clinical Significance of Anti-Ro/SSA Antibodies in Patients with Systemic Sclerosis: A Study from the EUSTAR Database
Blaz Burja¹, Marouane Boubaya², Patricia Carreira³, Christina Bergmann⁴, Lidia P Ananieva⁵, Gabriela Riemekasten⁶, Okada Masado⁷, Jeska de Vries-Bouwstra⁸, Edoardo Rosato⁹, Marie-Elise Truchetet¹⁰, Nicoletta Del Papa¹¹, Antonella Marcoccia¹², FABIOLA ATZENI¹³, Tim Schmeiser¹⁴, Madelon Vonk¹⁵, Francesco Del Galdo¹⁶, Oliver Distler¹⁷ and Muriel Elhai¹⁸, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²Department of Clinical Research, CHU Avicenne, APHP, Bobigny, France, ³Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴Department Internal Medicine, University Hospital Erlangen, Germany, Erlangen, Germany, ⁵V.A. Nasonova Research Institute Of Rheumatology Russian Federation, Moscow, Russia, ⁶University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, ⁷St.Luke's International Hospital Immuno-Rheumatology Center, Tokyo, Japan, ⁸Leiden University Medical Center, Leiden, Netherlands, ⁹Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy, ¹⁰Bordeaux University Hospital, Bordeaux, France, ¹¹Scleroderma Clinic, UOC Reumatologia Clinica, ASST G. Pini-CTO, Milano, Italy, ¹²Centro Di Riferimento Interdisciplinare Per La Sclerosi Sistemica, Rome, Italy, ¹³Rheumatology Unit, Univerity of Messina, Messina, Italy, ¹⁴Krankenhaus St. Josef, Wuppertal-Elberfeld, Germany, ¹⁵Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁶University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, ¹⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹⁸Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland
Background/Purpose: Despite the progress in understanding the patient heterogeneity in systemic sclerosis (SSc) based on SSc-specific antibodies, better risk stratification is needed. SSc non-specific antibodies…
Abstract Number: 0862 • ACR Convergence 2023
Role of CRTAC1 as a Biomarker of Osteoarthritis
Aneta Pekacova¹, Jiri Baloun², Adela Navratilova³, Lucia Ondrejcakova⁴, Jana Zborovjanova⁴, Petr Fulin⁵, Rastislav Ballay⁶, Michal Tomcik⁷ and Ladislav Senolt⁸, ¹First faculty of medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Hlavní město Praha, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵First Department of Orthopaedics, First Faculty of Medicine of Charles University and Motol University Hospital, Prague, Czech Republic, ⁶First Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ⁷Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁸Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic
Background/Purpose: Cartilage acidic protein-1 (CRTAC1) has been recently considered a promising biomarker of osteoarthritis (OA) progression (1,2). The aim of this study is to compare…
Abstract Number: 1147 • ACR Convergence 2023
Blood-Based Biomarkers of Inflammation and Tissue Remodeling Can Discriminate Between Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis and Are Associated with Hand Function
Helena Port I Linares¹, Birte Coppers², Sara Bayat², Godonou Elie-Tino², Larissa Valor-Mendez², David Simon², Filippo Fagni², Giulia Corte², Anne-Christine Bay-Jensen³, Koray Tascilar², Axel Hueber⁴, Verena Schoenau², Michael Sticherling⁵, Simon Heinrich⁶, Daniela Bohr², Georg Schett⁷, Arnd Kleyer⁸, Sigrid Leyendecker⁶, Signe Holm Nielsen³ and Anna-Maria Liphardt⁹, ¹Nordic Bioscience A/S / University of Copenhagen, Copenhagen, Denmark, ²Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology / Deutsches Zentrum Immuntherapie, Erlangen, Germany, ³Nordic Bioscience, Herlev, Denmark, ⁴Division of Rheumatology, Klinikum Nürnberg, Paracelsus Medical University / Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Nürnberg, Germany, ⁵Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Dermatology, Erlangen, Germany, ⁶Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Institute of Applied Dynamics, Erlangen, Germany, ⁷Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁸University Hospital Erlangen, Erlangen, Germany, ⁹Friedrich-Alexander-University Erlangen-Nuremberg, Internal Medicine 3 - Rheumatology and Immunology, University Hospital Erlangen, Erlangen, Germany
Background/Purpose: Inflammatory musculoskeletal diseases including rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are characterized by physical function impairment due to progressive inflammatory and structural changes.…
Abstract Number: 1409 • ACR Convergence 2023
Analysis of Soluble Biomarkers in Axial Spondyloarthritis
Caroline Bauchiero¹, Stephanie Sinnappan² and Joerg Ermann³, ¹Brigham and Women's Hospital, Boston, MA, ²Columbia University, New York, NY, ³Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Distinguishing patients with axial spondyloarthritis (axSpA) from patients with other causes of chronic back pain remains a challenge. The lack of reliable biomarkers contributes…
Abstract Number: 1697 • ACR Convergence 2023
Molecular Characterisation of Remission and Lupus Low Disease Activity State (LLDAS) by Whole-Blood Transcriptome-Based Pathways in a Pan-European Systemic Lupus Erythematosus Cohort
Ioannis Parodis¹, Julius Lindblom¹, Guillermo Barturen², Rafaela Ortega Castro³, Ricard Cervera⁴, Jacques-Olivier Pers⁵, Fernanda Genre Romero⁶, Falk Hiepe⁷, Maria Gerosa⁸, Laszlo Kovacs⁹, Ellen De Langhe¹⁰, Silvia Piantoni¹¹, Georg Stummvoll¹², Carlos Vasconcelos¹³, Barbara Vigone¹⁴, Torsten Witte¹⁵, Marta Alarcon-Riquelme¹⁶ and Lorenzo Beretta¹⁷, ¹Karolinska Institutet, Stockholm, Sweden, ²Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, ³Hospital Reina Sofía, Cordoba, Spain, ⁴Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Centre Hospitalier Universitaire de Brest, Hospital de la Cavale Blanche, Brest, France, ⁶IDIVAL, Santander, Spain, ⁷Charité Universitatsmedizine - Berlin, Berlin, Germany, ⁸University of Milan, Milano, Italy, ⁹University of Szeged, Szeged, Hungary, ¹⁰Katholieke Universiteit Leuven and Universitair Ziekenhuis Leuven, Leuven, Belgium, ¹¹ASST Spedali Civili and University of Brescia, Brescia, Italy, ¹²Medical University Vienna, Baden, Austria, ¹³Centro Hospitalar do Porto, Porto, Portugal, ¹⁴Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, ¹⁵Dept of Immunology and Rheumatology, Hannover, Germany, ¹⁶Center for Genomics and Oncological Research (GENYO), Granada, Spain, ¹⁷Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Italy
Background/Purpose: Treating to remission or lupus low disease activity state (LLDAS) are conceptual frameworks for the management of SLE, but the biological milieus underlying these…
Abstract Number: 1842 • ACR Convergence 2023
Reduction in the Concomitant Ordering of Erythrocyte Sedimentation Rate and C-Reactive Protein Within the Rheumatology Clinics at an Academic Medical Center
Ruchi Desai¹, Nainesh Shah¹, Ray Zhang¹, Maria Bacalao², Haidy Galous³, David Karp¹ and Puneet Bajaj¹, ¹UT Southwestern Medical Center, Dallas, TX, ²UT Southwestern, Dallas, TX, ³UT Southwestern, Southlake, TX
Background/Purpose: ESR and CRP are two laboratory values usedto assess inflammation. There is data to support that CRPis superior to ESR to detect/monitor inflammation or…
Abstract Number: 2333 • ACR Convergence 2023
Dapirolizumab Pegol Impacts Important Immunologic Pathways in SLE: Pharmacodynamic Analysis of B Cell and Type I Interferon Pathways from a Phase 2b Trial
Ioana Cutcutache¹, Alex Powlesland¹, Andrew Skelton¹, Yunyun Sun¹, Matthew Page¹, George Stojan², Peter Lipsky³, Ania Skowera¹ and Christian Stach⁴, ¹UCB Pharma, Slough, United Kingdom, ²UCB, Baltimore, MD, ³AMPEL BioSolutions, Charlottesville, VA, ⁴UCB Pharma, Monheim am Rheim, Germany
Background/Purpose: The pivotal role of CD40-CD40L interactions in systemic lupus erythematosus (SLE) pathogenesis stems from the orchestration of a range of immune and inflammatory responses…
Abstract Number: 2371 • ACR Convergence 2023
Plasma and Urine Cytokine Profiles in Active ANCA-Associated Vasculitis
Salem Almaani¹, Huijuan Song², Stacy Ardoin³, Lynn Fussner² and Brad Rovin², ¹Ohio State University Medical Center, Columbus, OH, ²Ohio State University, Columbus, OH, ³Nationwide Children's Hospital, Columbus, OH
Background/Purpose: ANCA-associated vasculitis (AAV) is a multisystem autoimmune disease that often affects the kidneys. It is unclear why some patients with AAV have kidney involvement…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].